Three new main board IPO’s launched today on 24^th March 2026. Let’s understand which is suitable as per your portfolio.

Powerica is the strongest, relatively safer bet for most investors, Amir Chand looks interesting for growth‑plus‑cyclical food exports, and Sai Parenterals is a higher‑risk, speciality pharma play best suited to investors comfortable with sector and regulatory risk.

Snapshot: Powerica vs Sai Parenterals vs Amir Chand IPO

Detail	Powerica IPO	Sai Parenterals IPO	Amir Chand IPO
Sector	Power solutions (gensets, gas engines, services)	Pharma – injectables & parenterals	Basmati rice exports
Issue size	₹1,100 cr (large)	₹408.79 cr	₹440 cr
Fresh / OFS	Mix (details in RHP; includes fresh for debt repay)	Fresh ₹285 cr + OFS ₹123.79 cr	100% fresh ₹440 cr
Price band	₹375–₹395	₹372–₹392	₹201–₹212
Lot size (shares)	37 (min ~₹14,615)	38 (min ~₹14,136–₹14,896)	70 (min ~₹14,070–₹14,840)
Issue dates	24–27 Mar 2026	24–27 Mar 2026	24–27 Mar 2026
Listing	2 Apr 2026, BSE & NSE	2 Apr 2026, BSE & NSE	2 Apr 2026, BSE & NSE
Key use of funds	Debt repayment ₹525 cr + general purposes	Capex, R&D, working capital; partial promoter exit via OFS	Working capital, plant upgradation, general purposes

Brief Business Profiles

Powerica Ltd – Power Solutions Player

• Mumbai‑based power solutions company in diesel & gas gensets, distributed generation, O&M services.

• Plans to use ₹525 crore from fresh issue to repay borrowings (total bank debt ₹1,214.25 crore as of Feb 2026), improving leverage and interest costs.
• Post‑issue market cap expected near ₹5,000 crore at upper band.

Ideal for: Investors seeking larger, relatively established business with deleveraging angle.

Sai Parenterals Ltd – Pharma Injectables

• Pharma company making parenteral formulations (injectables) and related products.moneycontrol+2

• Issue mix: Fresh ₹285 crore for capex, capacity expansion, R&D, working capital; OFS ₹123.79 crore (31.57 lakh shares) by existing shareholders.
• Implied valuation around ₹1,700+ crore at upper band.

Ideal for: Investors comfortable with pharma/regulatory risk and looking at speciality formulations.

Amir Chand Jagdish Kumar Exports Ltd – Basmati Rice

• Delhi‑based basmati rice exporter, selling branded and unbranded rice in domestic & export markets.

• 100% fresh issue ₹440 crore, no OFS – all proceeds to company for working capital, capacity expansion, brand building.
• Issue price band ₹201–₹212; lot size 70 shares.

Ideal for: Investors okay with agri‑commodity cyclicality, export and FX risk in exchange for growth potential.

Strengths –

Powerica IPO strengths

• Large, diversified power solutions business with sizeable order book (per RHP)
• Debt repayment of ₹525 crore improves balance sheet and interest coverage
• Participation from institutional anchors likely due to issue size (₹1,100 cr)
• Plays on power deficit, data centres, industrial capex cycles

Sai Parenterals IPO strengths

• Speciality injectables segment with higher entry barriers and better margins
• Mix of domestic + export formulations, diversified revenue streams
• Fresh funds for capacity, R&D, working capital support growth

Amir Chand IPO strengths

• Well‑known basmati exporter with established brand in select marketsbusiness
• 100% fresh issue – no promoter OFS; all money into business
• Structural demand for premium basmati rice in exports and domestic consumption

Key Risks –

Powerica IPO risks

• Capital‑intensive, cyclical power equipment business tied to capex cycles
• High starting debt (₹1,214 cr) even after repayment
• Competition from domestic and global genset players

Sai Parenterals IPO risks

• Regulatory and quality risk inherent to injectables (USFDA, other regulators)
• OFS component indicates partial profit‑taking by existing investors
• Pricing & margin pressure in crowded pharma segments

Amir Chand IPO risks

• Highly exposed to paddy prices, monsoon, MSP and export policy
• FX volatility, freight rates, and geopolitical factors hit margins
• Agri‑commodities can face sharp inventory and working‑capital swings

Which IPO to Subscribe?

Purely from a risk–reward and business quality lens (no GMP factor):

• Conservative / moderate‑risk investors
  • Powerica looks better placed: larger issue, deleveraging, diversified industrial clientele, potential institutional support.
• Sector‑specialist pharma investors
  • Sai Parenterals may appeal for formulation growth, but expect higher regulatory risk and need to study RHP margins carefully.
• High‑risk, cyclical/agri investors
  • Amir Chand can work if you’re comfortable with rice export cycles and policy risk; can be rewarding but volatile.

If you must prioritise:

1. Powerica IPO – Priority 1 (core apply)
2. Amir Chand IPO – Priority 2 (selective, higher risk)
3. Sai Parenterals IPO – Priority 3 (only if you like pharma and can handle volatility)

FAQs

Q1. All three IPOs open on the same day; can I apply to all?
Yes, you can apply to all three as long as you stay within retail limit of ₹2 lakh per IPO and have sufficient funds and UPI limits.

Q2. Which IPO is best for relatively safer listing and business quality?
Based on size, deleveraging use of funds, and diversified B2B profile, Powerica is relatively better for conservative investors compared to sector‑specific Sai Parenterals and cyclical Amir Chand.

Q3. Which IPO has only fresh issue and no OFS?
Amir Chand IPO is 100% fresh issue of ₹440 crore; Speciality and Powerica have fresh + OFS or mixed structures.

Q4. Are all three mainboard IPOs?
Yes, Powerica, Sai Parenterals and Amir Chand are all mainboard IPOs listing on BSE and NSE with similar bidding window 24–27 March 2026 and listing on 2 April 2026.

Q5. Should decision be based only on GMP and listing gains?
No. GMP is unofficial and volatile. Base your call on business quality, valuations (when available), use of funds, sector comfort and risk appetite, then use GMP only as a supporting data point.